Malfertheiner P, Bellutti M
Klinik für Gastroenterologie, Hepatologie und Infektiologie, Otto-v.-Guericke Universität, Leipziger Strasse 44, 39120 Magdeburg, Germany.
Internist (Berl). 2006 Jun;47(6):588, 590-5. doi: 10.1007/s00108-006-1630-y.
Treatment of peptic ulcer disease has undergone a radical change due to the discovery of its main cause, the Helicobacter pylori infection. The management of the chronic infection is now the primary aim. Treatment of peptic ulcer essentially consists of eradicating H. pylori. A current problem is the resistance developed by H. pylori to the antibiotics used in eradication regimen. Ulcers that are induced by nonsteroidal antirheumatic (NSAR) agents and acetylsalicylic acid are gaining in importance. Optimized inhibition of acid secretion with proton pump inhibitors has made it possible to both prevent and cure ulcers in the stomach and duodenum caused by NSAR agents.
由于发现了消化性溃疡病的主要病因——幽门螺杆菌感染,其治疗方法发生了根本性的变化。目前,对这种慢性感染的控制是主要目标。消化性溃疡的治疗主要是根除幽门螺杆菌。当前的一个问题是幽门螺杆菌对根除方案中使用的抗生素产生了耐药性。非甾体类抗风湿药(NSAR)和乙酰水杨酸所致的溃疡正变得越来越重要。质子泵抑制剂对胃酸分泌的优化抑制使得预防和治愈由NSAR药物引起的胃和十二指肠溃疡成为可能。